Invivyd, Inc. — Director's Dealing 2022

Sep 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adagio Therapeutics, Inc. (ADGI)
CIK: 0001832038
Period of Report: 2022-09-01

Reporting Person: Hering David (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-01	Common Stock	P	8000	$4.52	Acquired	8000	Direct

Footnotes

F1: The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $4.515 to $4.52. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.